Prediction: This Top Growth Stock Will Outperform the Market in the Next Decade

Medical device specialist DexCom (NASDAQ: DXCM) has substantially underperformed the market over the trailing-12-month period. The diabetes-focused company disappointed investors last year due to unimpressive financial results, especially in the second and third quarters.However, despite its recent woes, DexCom still looks like an excellent long-term option for growth-oriented investors. In fact, the company could beat the market in the next decade. Read on to find out why.DexCom develops continuous glucose monitoring (CGM) devices that help diabetes patients track their sugar levels constantly, allowing them to make better decisions for their health.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool